Endocannabinoids in endocrine and related tumours

Endocrine-Related Cancer

Volumn 15, Issue 2, 2008, Pages 391-408

  Bifulco, Maurizio ^a   Malfitano, Anna Maria ^a   Pisanti, Simona ^a   Laezza, Chiara ^b  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CORTICOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOCANNABINOID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; RIMONABANT; VANILLOID RECEPTOR 1;

ADENOMA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CALCIUM MOBILIZATION; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DOWN REGULATION; ENZYMATIC DEGRADATION; GENE MUTATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNOSTIMULATION; MALIGNANT TRANSFORMATION; NICK END LABELING; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PHASE TRANSITION; PHEOCHROMOCYTOMA; PROLACTINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; STROMA CELL; THYROID CANCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION;

ENDOCANNABINOIDS; ENDOCRINE GLAND NEOPLASMS; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 45849141305     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0258     Document Type: Review

References (152)

1. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J & Bartek J 2005 DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 864-870.
2. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offerta ler L, Mo F-M, Liu J & Kunos G 2005 Evidence for novel cannabinoid receptors. Pharmacology and Therapeutics 106 133-145.
3. Bello-Deocampo D & Tindall DJ 2003 TGF-b/Smad signaling in prostate cancer. Current Drug Targets 4 197-207.
4. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG & Moses HL 2004 TGF-b signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 848-850.
5. Bifulco M & Di Marzo V 2002 Targeting the endocannabinoid system in cancer therapy: a call for further research. Nature Medicine 8 547-550.
6. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L & Di Marzo V 2001 Control by the endogenous cannabinoid system of ras oncogene-dependent tumour growth. FASEB Journal 15 2745-2747.
7. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G & Di Marzo V 2004 A new strategy to block tumour growth by inhibiting endocannabinoid inactivation. FASEB Journal 18 1606-1608.
8. Bifulco M, Laezza C, Pisanti S & Gazzerro P 2006 Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology 148 123-135.
9. Bifulco M, Gazzerro P, Laezza C & Pentimalli F 2007a Endocannabinoids as emergine suppressors of angiogenesis and tumor invasion. Oncology Reports 4 813-816.
10. Bifulco M, Grimaldi C, Gazzerro P, Pisanti S & Santoro A 2007b Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular Pharmacology 71 1445-1456.
11. Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S & Di Marzo V 1998 Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. European Journal of Biochemistry 254 634-642.
12. Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL & Guzman M 2003 Inhibition of tumour angiogenesis by cannabinoids. FASEB Journal 17 529-531.
13. Bonaccorsi L, Marchiani S, Muratori M, Forti G & Baldi E 2004 Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. Journal of Cancer Research and Clinical Oncology 130 604-614.
14. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G & Casellas P 1995 Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochemical Journal 312 637-641.
15. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrié B, Rinaldi-Carmona M, Calandra B, Le Fur G & Casellas P 1996 Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. European Journal of Biochemistry 237 704-711.
16. Braga-Basaria M & Ringel MD 2003 Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. Journal of Clinical Endocrinology and Metabolism 88 1947-1960.
17. Caffarel MM, Sarrio D, Palacios J, Guzman M & Sanchez C 2006 Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Research 66 6615-6621.
18. Caldon CE, Daly RJ, Sutherland RL & Musgrove EA 2006 Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry 97 261-274.
19. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D & Rabbani SA 2004 Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 1345-1356.
20. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT & Tomaszewski JE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. American Journal of Pathology 146 695-705.
21. Coleman ML, Marshall CJ & Olson MF 2004 RAS and RHO GTPases in G1-phase cell-cycle regulation. Nature Reviews. Molecular Cell Biology 5 355-366.
22. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumour cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
23. Culig Z, Comuzzi B, Steiner H, Bartsch G & Hobisch A 2004 Expression and function of androgen receptor coactivators in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 92 265-271.
24. Culig Z, Steiner H, Bartsch G & Hobisch A 2005 Interleukin-6 regulation of prostate cancer cell growth. Journal of Cellular Biochemistry 95 497-505.
25. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM & Isaacs JT 2003 Dissociation between androgen responsiveness for malignant growth vs expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54 249-257.
26. Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, Gelman M & Girault JA 1996 Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273 1719-1722.
27. Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M & Casellas P 1998 The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Letters 425 419-425.
28. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A & Mechoulam R 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 1946-1949.
29. Edwards DP 2005 Regulation of signal transduction pathways by estrogen and progesterone. Annual Review of Physiology 67 335-376.
30. Erlandsson N, Baumann B, Rössler OG, Kaufmann K, Giehl KM, Wirth T & Thiel G 2002 Lack of correlation between NF-κB activation and induction of programmed cell death in PC12 pheochromocytoma cells treated with 6-hydroxydopamine or the cannabinoid receptor 1-agonist CP55,940. Biochemical Pharmacology 64 487-495.
31. Fan L, Pedicelli CV, Dibble CC, Catbagan W, Zarycki JL, Laciak R, Gipp J, Shaw A, Lamm ML, Munoz A et al. 2004 Hedgehog signaling promotes prostate xenograft tumour growth. Endocrinology 145 3961-3970.
32. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL & Mitchell RL 1995 Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Molecular Pharmacology 48 443-450.
33. Fernandez-Ruiz JJ, Munoz RM, Romero J, Villanua MA, Makriyannis A & Ramos JA 1997 Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochemical Pharmacology 53 1919-1927.
34. Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C & Bologna M 2005 Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumour cell dissemination. Thrombosis and Haemostasis 93 964-975.
35. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G & Casellas P 1995 Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232 54-61.
36. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M & Guzman M 2000 Anti-tumoural action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 6 313-319.
37. Garrison JB & Kyprianou N 2004 Novel targeting of apoptosis pathways for prostate cancer therapy. Current Cancer Drug Targets 4 85-95.
38. Glass AG, Lacey JV Jr, Carreon JD & Hoover RN 2007 Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. Journal of the National Cancer Institute 99 1152-1161.
39. Glass M & Northup JK 1999 Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Molecular Pharmacology 56 1362-1369.
40. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC & Leung HY 2003 FGF8 isoform b expression in human prostate cancer. British Journal of Cancer 88 1432-1438.
41. Godoy-Tundidor S, Cavarretta IT, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A & Culig Z 2005 Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogenactivated protein kinase and phosphatidylinositol 3-kinase. Prostate 64 209-216.
42. Gomez Del Pulgar T, De Ceballos ML, Guzman M & Velasco G 2002a Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. Journal of Biological Chemistry 277 36527-36533.
43. Gomez del Pulgar T, Velasco G, Sanchez C, Haro A & Guzman M 2002b De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal 363 183-188.
44. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS & Wilson EM 2004 Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. Journal of Biological Chemistry 279 7119-7130.
45. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notarnicola M, Iacuzzo I, Portella G et al. 2006 Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 312 363-373.
46. Guo Y & Kyprianou N 1999 Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumourigenicity via induction of caspase-1-mediated apoptosis. Cancer Research 59 1366-1371.
47. Guzman M 2003 Cannabinoids: potential anticancer agents. Nature Reviews. Cancer 3 745-755.
48. Guzman M, Sanchez C & Galve-Roperh I 2001 Control of the cell survival/death decision by cannabinoids. Journal of Molecular Medicine 78 613-625.
49. Guzman M, Sanchez C & Galve-Roperh 12002 Cannabinoids and cell fate. Pharmacology and Therapeutics 95 175-184.
50. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I & Mechoulam R 2001 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CBl receptor. PNAS 98 3662-3665.
51. Henttu P, Lukkarinen O & Vihko P 1990 Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumours of the human prostate. International Journal of Cancer 45 654-660.
52. Howlett AC 1995 Pharmacology of cannabinoid receptors. Annual Review of Pharmacology and Toxicology 35 607-634.
53. Howlett AC 2002 The cannabinoid receptors. Prostaglandins & Other Lipid Mediators 68-69 619-631.
54. Huang SM, Lee JC, Wu TJ & Chow NH 2001 Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World Journal of Surgery 25 302-306.
55. Isaacs JT 1994 Role of androgens in prostatic cancer. Vitamins and Hormones 49 433-502.
56. Ittman M & Mansukhani A 1997 Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. Journal of Urology 157 351-356.
57. Jackson AL & Murphy LL 1997 Role of the hypothalamic-pituitary- adrenal axis in the suppression of luteinizing hormone release by D-9-tetrahydrocannabinol. Neuroendocrinology 65 446-452.
58. Jordà MA, Verbakel SE, Valk PJ, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agrò A, Löwenberg B & Deiwel R 2002 Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99 2786-2793.
59. Jordà AM, Rayman N, Tas M, Verbakel SE, Battista N, van Lom K, Lowenberg B, Maccarrone M & Delwel R 2004 The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104 526-534.
60. Kaplan BL, Rockwell CE & Kaminski NE 2003 Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. Journal of Pharmacolology and Experimental Therapeutics 306 1077-1085.
61. Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD & Jameson JL 1991 Ras oncogene mutations in benign and malignant thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 73 832-836.
62. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM & Beachy PA 2004 Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431 707-712.
63. Klein TW 2005 Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews. Immunology 5 400-441.
64. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A & Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 656-658.
65. Kim HG, Kassis J, Souto JC, Turner T & Wells A 1999 EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histolology and Histopathology 14 1175-1182.
66. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
67. Laezza C, Pisanti S, Crescenzi E & Bifulco M 2006 Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Letters 580 6076-6082.
68. Lara PN Jr, Twardowski P & Quinn DI 2004 Angiogenesis-targeted therapies in prostate cancer. Clinical Prostate Cancer 3 165-173.
69. Lee C, Sufkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS & Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136 796-803.
70. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B & Wynford-Thomas D 1989 High frequency of ras oncogene activation in all stages of human thyroid tumourigenesis. Oncogene 4 159-164.
71. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL & Tuttle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 552-558.
72. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M & Di Marzo V 2006 Antitumour activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics 318 1375-1387.
73. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A & Kunos G 2000 Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal 346 835-840.
74. Maccarrone M & Finazzi-Agrò A 2002 Endocannabinoids and their actions. Vitamins and Hormones 65 225-255.
75. MacDonald JC & Vaughan CW 2001 Cannabinoids act backwards. Nature 410 527-530.
76. Malaney S & Daly RJ 2001 The ras signaling pathway in mammary tumourigenesis and metastasis. Journal of Mammary Gland Biology and Neoplasia 6 101-113.
77. Di Marzo V 1998 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochimica et Biophysica Acta 1392 153-175.
78. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z & De Petrocellis L 2001 Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal 358 249-255.
79. Di Marzo V, Bifulco M & De Petrocellis L 2004 The endocannabinoid system and its therapeutic exploitation. Nature Reviews. Drug Discovery 3 771-784.
80. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC & Bonner TI 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 561-564.
81. McAllister SD & Glass M 2002 CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins, Leukotrienes, and Essential Fatty Acids 66 161-171.
82. McAllister SD, Christian RT, Horowitz MP, Garcia A & Desprez PY 2007 Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics 6 2921-2927.
83. McKallip RJ, Nagarkatti M & Nagarkatti PS 2005 Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumour immune response. Journal of Immunology 174 3281-3289.
84. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. 1995 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50 83-90.
85. Mechoulam R, Panikashvili D & Shohami E 2002 Cannabinoids and brain injury: therapeutic implications. Trends in Molecular Medicine 8 58-61.
86. Mechoulam R, Peters M, Murillo-Rodriguez E & Hanus LO 2007 Cannabidiol - recent advances. Chemistry & Biodiversity 4 1678-1692.
87. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M & Di Marzo V 1999a Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochemical and Biophysical Research Communications 262 275-284.
88. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M & Di Marzo V 19996 Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters 463 235-240.
89. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M & Di Marzo V 2000 Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 118-126.
90. Mimeault M, Pommery N & Henichart JP 2003a New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors 21 1-14.
91. Mimeault M, Nicole P, Nicole W, Christian B & Jean-Pierre H 2003b Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56 1-12.
92. Mimeault M, Moore E, Moniaux N, Henichart JP, Depreux P, Lin MF & Batra SK 2006 Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. International Journal of Cancer 118 1022-1031.
93. Mizukami Y, Nonomura A, Hashimoto T, Kawahara E, Matsukawa S & Matsubara F 1988 Immunohistochemical demonstration of ras p21 oncogene product in normal, benign, and malignant human thyroid tissues. Cancer 61 873-880.
94. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF & Tindall DJ 1992 Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21 63-73.
95. Moschos SJ & Mantzoros CS 2002 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 64 317-332.
96. Motyl T & Gajewska M 2004 IGF-binding proteins mediate TGF-b1-induced apoptosis in bovine mammary epithelial BME-UV1 cells. Comparative Biochemistry and Physiology. Toxicology & Pharmacology 139 65-75.
97. Munro S, Thomas KL & Abu-Shaar M 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 61-65.
98. Mydlo JH, Michaeli J, Heston WD & Fair WR 1988 Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 13 241-247.
99. Namba H, Rubin SA & Fagin JA 1990 Point mutations of ras oncogenes are an early event in thyroid tumourigenesis. Molecular Endocrinology 4 1474-1479.
100. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D & Gee JM 2004 Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 346S-354S.
101. Nickerson T, Huynh H & Pollak M 1997 Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells. Biochemical and Biophysical Research Communications 237 690-693.
102. Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ & Campbell WB 2004 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Research 64 8826-8830.
103. Okamoto M, Lee C & Oyasu R 1997 Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Research 57 141-146.
104. Olsen CL, Hsu PP, Glienke J, Rubanyi GM & Brooks AR 2004 Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumours. BMC Cancer 4 43.
105. Orio F Jr, Terouanne B, Georget V, Lumbroso S, Avances C, Siatka C & Sultan C 2002 Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Molecular and Cellular Endocrinology 198 105-114.
106. Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grübler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V et al. 2001 Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. Journal of Clinical Endocrinology and Metabolism 86 2687-2696.
107. Pagotto U, Marsicano G, Cota D, Lutz B & Pasquali R 2006 The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews 27 73-100.
108. Parolaro D, Massi P, Rubino T & Monti E 2002 Endocannabinoids in the immune system and cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids 66 319-332.
109. Pertwee RG 1997 Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics 74 129-180.
110. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M & Di Marzo V 1998 The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. PNAS 95 8357-8380.
111. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG & Di Marzo V 2000 Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters 483 52-56.
112. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D & Di Marzo V 2002 Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundamental and Clinical Pharmacology 16 297-302.
113. De Petrocellis L, Marini P, Matias I, Moriello AS, Starowicz K, Cristino L, Nigam S & Di Marzo V 2007 Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Experimental Cell Research 313 2993-3004.
114. Pisanti S, Borselli C, Oloviero O, Laezza C, Gazzerro P & Bifulco M 2006 Antiangiogenetic activity of the endocannabinoid anandamide. Correlation to its tumour-suppressor efficacy. Journal of Cellular Physiology 211 495-503.
115. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V & Bifulco M 2003 Inhibitory effects of cannabinoid CB1 receptor stimulation on tumour growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB Journal 17 1771-1773.
116. Porter AC & Felder CC 2001 The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacology & Therapeutics 90 45-60.
117. Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T & Liu WM 2005 Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105 1214-1221.
118. Ropiquet F, Giri D, Lamb DJ & Ittman M 1999 FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. Journal of Urology 162 595-599.
119. Rueda D, Galve-Roperh I, Haro A & Guzmán M 2000 The CB(1) cannabinoid receptor is coupled to the activation of c-Jun c-terminal kinase. Molecular Pharmacology 58 814-820.
120. Sanchez C, Galve-Roperh I, Canova C, Brachet P & Guzman M 1998 Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Letters 436 6-10.
121. Sánchez C, Rueda D, Ségui B, Galve-Roperh I, Levade T & Guzmán M 2001 The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Molecular Pharmacology 59 955-959.
122. Sanchez MG, Ruiz-Llorente L, Sanchez AM & Diaz-Laviada I 2003a Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cellular Signalling 15 851-859.
123. Sanchez MG, Sanchez AM, Ruiz-Llorente L & Diaz-Laviada I 2003b Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Letters 555 561-566.
124. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, Beyna M, Datta MW, Datta S & Altaba A 2004 Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. PNAS 101 12561-12566.
125. Sarfaraz S, Afaq F, Adhami VM & Mukhtar H 2005 Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Research 65 1635-1641.
126. Sarfaraz S, Afaq F, Adhami VM, MaUk A & Mukhtar H 2006 Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. Journal of Biological Chemistry 281 39480-39491.
127. Sarker KP, Obara S, Nakata M, Kitajima I & Maruyama I 2000 Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Letters 472 39-44.
128. Sarker KP, Biswas KK, Yamakuchi M, Lee KY, Hahiguchi T, Kracht M, Kitajima I & Maruyama I 2003 ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. Journal of Neurochemistry 85 50-61.
129. Sarnataro D, Grimaldi C, Pisanti S, Gazzerro P, Laezza C, Zurzolo C & Bifulco M 2005 Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Letters 579 6343-6349.
130. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C & Bifulco M 2006 The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Molecular Pharmacology 70 1298-1306.
131. Semenza GL 2003 Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer 3 721-732.
132. Sloan EK, Stanley KL & Anderson RL 2004 Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23 7893-7897.
133. Sorensen CS, Syljuasen RG, Falck J, Schroeder T, Ronnstrand L, Khanna KK, Zhou BB, Bartek J & Lukas J 2003 Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3 247-258.
134. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS & Redwine E 1987 Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medicine 317 909-916.
135. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G & Kaaks R 2004 High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. Journal of Clinical Oncolology 22 3104-3112.
136. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A & Waku K 1995 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications 215 89-97.
137. Sugiura T, Kobayashi Y, Oka S & Waku K 2002 Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes, and Essential Fatty Acids 66 173-192.
138. Taplin ME & Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry 91 483-490.
139. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E & Hynes NE 2003 ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 56 142-149.
140. Tsang M & Dawid IB 2004 Promotion and attenuation of FGF signaling through the Ras-MAP kinase pathway. Science's STKE 228 317.
141. Tuttle RM, Fleisher M, Francis GL & Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. Journal of Clinical Endocrinology and Metabolism 87 1737-1742.
142. Uto K, Inoue D, Shimuta K, Nakajo N & Sagata N 2004 Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism. EMBO Journal 23 3386-3396.
143. Verras M, Brown J, Li X, Nusse R & Sun Z 2004 Wnt3a growth factor induces androgen receptor-mediated transcription and deregulated gene products and targeting therapies for prostate cancer enhances cell growth in human prostate cancer cells. Cancer Research 64 8860-8866.
144. Visvader J & Lindeman G 2003 Transcriptional regulators in mammary gland development and cancer. International Journal of Biochemistry and Cell Biology 35 1034-1051.
145. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG & Lisanti MP 2004 Caveolin-1 gene disruption promotes mammary tumourigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. Journal of Biological Chemistry 279 51630-51646.
146. Wilson RI & Nicoll RA 2002 Endocannabinoid signaling in the brain. Science 296 678-682.
147. Wu S-F, Sun H-Z, Qi X-D & Tu Z-H 2001 Effect of Epristeride on the expression of IGF-1 and TGF-b receptors in androgen-induced castrated rat prostate. Experimental Biology and Medicine 226 954-960.
148. Yamada S, Taketomi T & Yoshimura A 2004 Model analysis of difference between EGF pathway and FGF pathway. Biochemical and Biophysical Research Communications 314 1113-1120.
149. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT & Chang C 2003 Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochemical and Biophysical Research Communications 305 462-469.
150. Ye D, Mendelsohn J & Fan Z 1999 Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clinical Cancer Research 5 2171-2177.
151. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J & Kypta RM 2004 Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Research 64 7918-7926 Errata 65 8057.
152. Zygmunt PM, Julius I, Di Marzo I & Hogestatt ED 2000 Anandamide - the other side of the coin. Trends in Pharmacological Sciences 21 43-44.